PT - JOURNAL ARTICLE AU - Miguel Garcia-Knight AU - Khamal Anglin AU - Michel Tassetto AU - Scott Lu AU - Amethyst Zhang AU - Sarah A. Goldberg AU - Adam Catching AU - Michelle C. Davidson AU - Joshua R. Shak AU - Mariela Romero AU - Jesus Pineda-Ramirez AU - Ruth Diaz Sanchez AU - Paulina Rugart AU - Kevin Donohue AU - Jonathan Massachi AU - Hannah M. Sans AU - Manuella Djomaleu AU - Sujata Mathur AU - Venice Servellita AU - David McIlwain AU - Brice Gaudiliere AU - Jessica Chen AU - Enrique O. Martinez AU - Jacqueline M. Tavs AU - Grace Bronstone AU - Jacob Weiss AU - John T. Watson AU - Melissa Briggs-Hagen AU - Glen R. Abedi AU - George W. Rutherford AU - Steven G. Deeks AU - Charles Chiu AU - Sharon Saydah AU - Michael J. Peluso AU - Claire M. Midgley AU - Jeffrey N. Martin AU - Raul Andino AU - J. Daniel Kelly TI - Infectious viral shedding of SARS-CoV-2 Delta following vaccination: a longitudinal cohort study AID - 10.1101/2022.05.15.22275051 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.15.22275051 4099 - http://medrxiv.org/content/early/2022/05/19/2022.05.15.22275051.short 4100 - http://medrxiv.org/content/early/2022/05/19/2022.05.15.22275051.full AB - The impact of vaccination on SARS-CoV-2 infectiousness is not well understood. We compared longitudinal viral shedding dynamics in unvaccinated and fully vaccinated adults. SARS-CoV-2-infected adults were enrolled within 5 days of symptom onset and nasal specimens were self-collected daily for two weeks and intermittently for an additional two weeks. SARS-CoV-2 RNA load and infectious virus were analyzed relative to symptom onset stratified by vaccination status. We tested 1080 nasal specimens from 52 unvaccinated adults enrolled in the pre-Delta period and 32 fully vaccinated adults with predominantly Delta infections. While we observed no differences by vaccination status in maximum RNA levels, maximum infectious titers and the median duration of viral RNA shedding, the rate of decay from the maximum RNA load was faster among vaccinated; maximum infectious titers and maximum RNA levels were highly correlated. Furthermore, amongst participants with infectious virus, median duration of infectious virus detection was reduced from 7.5 days (IQR: 6.0-9.0) in unvaccinated participants to 6 days (IQR: 5.0-8.0) in those vaccinated (P=0.02). Accordingly, the odds of shedding infectious virus from days 6 to 12 post-onset were lower among vaccinated participants than unvaccinated participants (OR 0.42 95% CI 0.19-0.89). These results indicate that vaccination had reduced the probability of shedding infectious virus after 5 days from symptom onset.Significance statement We present longitudinal data on the magnitude, duration and decay rate of viral RNA and the magnitude and duration of infectious virus in nasal specimens from vaccinated and unvaccinated participants. On average, vaccinated participants (infected with the highly transmissible Delta variant) showed a lower probability of having infectious virus after 5 days of symptoms compared to unvaccinated participants (infected with mostly pre-delta viral lineages), even though both groups had a similar magnitude of infectious virus at or near the peak. These data help improve our understanding of the duration of the infectious period when infection occurs following vaccination and serves as a reference for future studies of shedding dynamics following infections with novel variants of concern.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Centers for Disease Control and Prevention Broad Agency Announcement. The National Institute of Allergy and Infectious Diseases also supported JDK during this study (K23 grant number AI146268), but this funding source had no role in the content of the manuscript nor the decision for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by the University of California Institutional Review Board and given a designation of public health surveillance according to federal regulations as summarized in 45 CFR 46.102(d)(1)(2). Written informed consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors